arc fusion protein sl-279252
Generic: ARC Fusion Protein SL-279252
arc fusion protein sl-279252: 1 clinical trial tracked.
arc fusion protein sl-279252 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about arc fusion protein sl-279252, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Primary endpoint: Safety Profile of SL-279252
Interventionalopen49 enrolledStarted 2019-03Completion 2023-055 sites · Belgium, Canada, Spain, United StatesShattuck Labs, Inc.